Bio tech company updates — 11/11/2026
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
Korean biotech firms are intensifying global expansion efforts this week, with major delegations attending BIO-Europe 2026 in Cologne and launching new US-focused support platforms. Concurrently, domestic policy shifts are underway, including a new bioscience institute in Incheon and a strategic pivot in government funding models to better support late-stage clinical trials.
Key Findings
- BIO-Europe Delegation: Five prominent Korean biotech companies—Alteogen, D&D Pharmatech, Ligachem Biosciences, ABL Bio, and G2Gbio—are actively pitching obesity and cancer drug candidates to potential partners at BIO-Europe 2026 in Cologne.
- New US Market Support: KOTRA has selected 31 Korean biotech firms for the "K-Bio Global Innovation Links" program in New Jersey to facilitate their entry into the United States market. SK Biopharmaceuticals also launched its U.S. LinX platform specifically to support these 31 firms.
- Incheon’s Strategic Pivot: The city of Incheon launched a preparatory committee to establish IBIST, a new bioscience institute aimed at moving beyond contract manufacturing toward core technology development and research talent cultivation.
- Funding Model Critique: Industry analysts argue that while royalty income is rising (e.g., Yuhan’s $27 million from Lazertinib), state funding for late-stage trials lags behind Chinese competitors, necessitating a shift from seed money to investment-based support.
Details
Global Expansion via BIO-Europe 2026
The industry’s largest European dealmaking event, BIO-Europe 2026, serves as the current focal point for Korean biotech internationalization. Running until November 11, the event sees over 3,200 companies from more than 60 countries participating.
South Korean firms are aggressively pursuing licensing and partnership deals. Specifically, Alteogen, D&D Pharmatech, Ligachem Biosciences, ABL Bio, and G2Gbio are presenting assets in high-demand therapeutic areas such as obesity and oncology. Additionally, Bioneer reported significant interest in its SAMiRNA-based hair loss treatments from global drugmakers during the conference. As of November 10, no major deals had been officially announced, but talks were ongoing for cancer treatments, liver disease drugs, and drug-delivery technologies.
Structural Support for US Market Entry
To complement trade show efforts, institutional support mechanisms have been activated. KOTRA, alongside six partner institutions, finalized the selection of 31 biotech firms for the K-Bio Global Innovation Links program based in New Jersey.
SK Biopharmaceuticals concurrently launched the U.S. LinX platform to provide logistical and regulatory support to these same 31 companies, aiming to streamline their commercialization pathways in North America.
Domestic Infrastructure and Policy Shifts
On the domestic front, Incheon is restructuring its bioscience ecosystem. A preparatory committee has been established for IBIST (Incheon Bio Science Institute), which aims to shift the local industry focus from contract manufacturing organizations (CMOs) to core research and development capabilities.
Furthermore, economic analyses highlight a critical gap in late-stage clinical trial funding. While companies like Yuhan are seeing tangible returns from royalties—projecting approximately 40 billion won ($27 million) this year from Lazertinib—the report suggests that seed money alone is insufficient compared to the mega-funds available to Chinese competitors. This has spurred calls for government R&D support to transition from grants to equity-style investments (Note: This specific article is dated Nov 5, but is referenced in the context of the Nov 9 analysis of funding gaps).
Sources
Korean Biotechs Head to BIO-Europe to Pitch Obesity, Cancer Drugs - Seoul Economic Daily
Korea
Korean biotechs pitch drug candidates at BIO-Europe | Aju Press
KOTRA Picks 31 Biotech Firms for U.S. Market Push - Seoul Economic Daily
Korean biotechs pitch cancer drugs at BIO-Europe | Aju Press
ajupress.com
biz.chosun.com
en.sedaily.com
biz.chosun.com
biz.chosun.com
en.sedaily.com
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
